Singapore markets closed

Straits Times Index
3,313.48
+8.49(+0.26%)
Nikkei
38,787.38
-132.88(-0.34%)
Hang Seng
19,553.61
+177.08(+0.91%)
FTSE 100
8,420.26
-18.39(-0.22%)
Bitcoin USD
66,540.75
+1,436.78(+2.21%)
CMC Crypto 200
1,364.91
-8.94(-0.65%)

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

132.66

-0.02

(-0.02%)

As of 02:05PM EDT. Market open.

Trade prices are not sourced from all markets

Press releases

ACCESSWIRE
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against ...
PR Newswire
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage
Business Wire
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
RAHWAY, N.J. & CAMBRIDGE, Mass., December 11, 2023--Merck and Moderna Initiate INTerpath-002 Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA for Certain Types of Resected NSCLC